Expanded GXP compliance increases Concept's breadth of services
Successful MHRA inspection at Dundee site confirms GLP accreditation for in vitro safety studies and bioanalysis.
Concept Life Sciences has completed the first phase of its GXP compliance plan, achieving GLP (good laboratory practice) accreditation of its Dundee site for in vitro safety studies and bioanalysis.
The successful MHRA inspection was done at Concept’s Dundee site in December 2017, confirming GLP accreditation for in vitro safety studies and bioanalysis. The accreditation increases the breadth of services the company is able to offer to customers requiring regulatory studies, and provides assurance of data integrity and compliance with international standards, ensuring acceptance of the data by global regulatory bodies.
The accreditation forms part of a phased plan over H1 2018 to expand GXP compliance (including GLP and GMP) at the company’s facilities across the UK, to expand services to manufacture of API material, and to further support development of compounds from the discovery stage to full IND packages.
John Handley, Chief Operating Officer, Concept Life Sciences, said: “Concept Life Sciences has a strategy in place to expand GXP compliance across multiple sites, as part of our drive to expand the services we offer to our clients. We are delighted that the Dundee site has achieved GLP certification, and look forward to announcing the next stage in the growth of the company.”
GLP refers to a quality system of management controls to ensure uniformity, consistency, reliability, reproducibility, quality and integrity in non-clinical laboratory studies and gives confidence in the safety assessment of a compound. GLP applies to the pharmaceutical industry and the required non-clinical animal testing that must be performed prior to approval of new drug products, and to many other non-pharmaceutical agents such as colour additives, food additives, food contamination limits, food packaging, and medical devices.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.